ISCO 10-Q: Going-Concern Doubt Cleared After $25.6M LCT Sale; $2.4M Executive Bonus Disclosed
ISCO sits 54% above its 52-week low of $0.11.
Summary
ISCO's Q3 10-Q books a $21.8 million gain on the LCT sale, lifts cash to $20.0 million and removes the going-concern warning, while disclosing a $2.4 million executive bonus paid in October.
Key Events · Earnings and Guidance · ISCO
-
LCT Sale Closes, Gain Booked
Total consideration of $25.6 million ($23.1 million net cash plus $2.6 million escrow) produced a $21.8 million pre-tax gain, driving $21.8 million of Q3 net income.
-
Going-Concern Doubt Removed
Management concluded the conditions that previously raised substantial doubt 'have been alleviated and that substantial doubt no longer exists,' citing $20.0 million of cash at September 30 versus $0.8 million at December 31, 2025.
-
CEO Note Repaid in Full
The related party note to Dr. Semechkin was settled in September 2026 with $2.35 million of principal and $0.9 million of accrued interest; no balance remains.
-
Continuing Business Still Loss-Making
Nine-month product sales were $444 thousand and the net loss from continuing operations was $2,465 thousand, so the remaining LSC skin-care and therapeutic segments do not yet fund operations.
Analysis · ISCO · Life Sciences
The LCT sale closed September 1, 2026, and while the 8-K already reported the headline numbers, this 10-Q is where the accounting lands: a $21.8 million pre-tax gain turns the quarter into $21.8 million of net income, and management now says the substantial doubt about the company's ability to continue as a going concern no longer exists. Cash stood at $20.0 million at September 30 versus $0.8 million at year-end, and the $2.35 million related party note owed to CEO Dr. Semechkin plus $0.9 million of accrued interest was repaid in full. Against that, the remaining business is tiny and still losing money — $444 thousand of nine-month product sales and a $2.5 million loss from continuing operations — so the story is now about how fast the proceeds are consumed. Notably for governance, given the company's size and history of losses, the board on October 19 approved a $2.4 million one-time executive cash bonus, paid October 20.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ISCO was trading at $0.17 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.11 to $0.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.